Tudor Investment Corp
JSPR icon

Tudor Investment Corp’s Jasper Therapeutics JSPR Stock Holding History

Tudor Investment Corp’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,000
Closed -$205K – 2722
2021
Q3 		$205K Buy
+2,000
New +$204K ﹤0.01% 2295

Other funds holding JSPR

QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GC
Grace Capital Quincy, Massachusetts $168M AUM 21.6% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Tudor Investment Corp's JSPR Position: Q4 2021 in Review

Tudor Investment Corp sold out of Jasper Therapeutics (JSPR) in Q4 2021, closing a stake of 2,000 shares — an estimated $205K sold.

Tudor Investment Corp first reported a position in JSPR in Q3 2021 and held it in 1 quarter. The position peaked at $205K in Q3 2021. 25 funds tracked by Wall St. Rank hold JSPR as of Q4 2021.

  • Tudor Investment Corp reported no remaining Jasper Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Tudor Investment Corp sold 2,000 Jasper Therapeutics shares in Q4 2021, an estimated $205K.
  • Tudor Investment Corp first reported a position in Jasper Therapeutics in Q3 2021 and held it in 1 quarter.
  • Tudor Investment Corp's Jasper Therapeutics position peaked at $205K in Q3 2021.
  • 25 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q4 2021.

Based on Tudor Investment Corp's 13F filing for Q4 2021, filed 14 Feb 2022.